> France's IntegraGen has picked up the exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression-free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. Release
> BioMarker Strategies named Jerry Parrott as president, CEO and director. More